Showing results (651-660 of 1,173) with videos related to
Sort By:
Pageof 118
Nature Ecology & Evolution|May 16, 2018
Origin and maintenance of chemical diversity in a species-rich tropical tree lineageDiego Salazar, John Lokvam, Italo Mesones, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Radiosurgery as part of the initial management of patients with malignant gliomasJ S Loeffler, E Alexander, W M Shea, et al.Frontiers in Plant Science|July 5, 2018
Divergent Secondary Metabolites and Habitat Filtering Both Contribute to Tree Species Coexistence in the Peruvian AmazonJason Vleminckx, Diego Salazar, Claire Fortunel, et al.Cancer|February 10, 2010
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomasFabio M Iwamoto, Teri N Kreisl, Lyndon Kim, et al.Journal of Biomedical Informatics|September 11, 2010
Gene pathways and subnetworks distinguish between major glioma subtypes and elucidate potential underlying biologyStefan Wuchty, Alice Zhang, Jennifer Walling, et al.The Canadian Journal of Plastic Surgery = Journal Canadien De Chirurgie Plastique|April 20, 2013
Cosmetic outcomes following head and neck melanoma reconstruction: The patient's perspectiveDonald Buck, Vinay Rawlani, Jeffrey Wayne, et al.Neurosurgery|February 1, 1995
Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiformeD C Shrieve, E Alexander, P Y Wen, et al.Clinical Pharmacology and Therapeutics|January 1, 1984
Digoxin biotransformationM H Gault, L L Longerich, J C Loo, et al.Neuro-Oncology|February 13, 2010
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasTeri N Kreisl, Svetlana Kotliarova, John A Butman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trialStuart A Grossman, Xiaobu Ye, Marc Chamberlain, et al.Pageof 118